Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Eligibility criteria Inclusion criteria: * Histologically documented adenocarcinoma of the breast * ANC \> 1000 cells * Female; age \> 18 * Zubrod PS 0-1 * Platelets \> 100,000 * Stage IIA-IIIB disease * Total bilirubin \< 1.5 ULN * No evidence of any metastatic disease * Serum Creatinine \< 1.5 gm/dl * No prior systemic therapy for breast cancer or Creat Cl \> 30 ml/min * Not pregnant or lactating * Serum ALT \< 2.0 ULN * ER, PR and HER2 status required * LVEF (MUGA/echo WNL) * No baseline \> 2 neuropathy * Urine protein: creat ratio \< 1.0 * HER2-negative - either IHC 0-1+ or FISH ratio \< 2.0 * Hemoglobin \> 9 gm/dl * (FISH testing is required for all HER2 2-3+ tumors by IHC) Exclusion criteria: * No Histologically documented adenocarcinoma of the breast * No-ANC \> 1000 cells * Female; age \< 18 * Zubrod PS \> 0-1 * Platelets \< 100,000 * Stage IV disease * Total bilirubin \> 1.5 ULN * metastatic disease * Serum Creatinine \> 1.5 gm/dl * prior systemic therapy for breast cancer or Creat Cl \> 30 ml/min * pregnant or lactating * Serum ALT \> 2.0 ULN baseline \> 2 neuropathy * Urine protein: creat ratio \>1.0 * HER2-positive * Hemoglobin \< 9 gm/dl